Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 4, 2010, Pages 765-773

  Haluska, Paul ^a   Worden, Frank ^b   Olmos, David ^c   Yin, Donghua ^d   Schteingart, David ^b   Batzel, Gretchen N ^a   Paccagnella, M Luisa ^d   De Bono, Johann S ^c   Gualberto, Antonio ^d   Hammer, Gary D ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Adrenocortical carcinoma; CP 751,871; Figitumumab; IGF 1R; Monoclonal antibody

Indexed keywords

ANTINEOPLASTIC AGENT; FIGITUMUMAB; GLUCOSE; GROWTH HORMONE; INSULIN; TUMOR MARKER; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; SOMATOMEDIN C RECEPTOR;

ADRENAL CORTEX CARCINOMA; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTACT DERMATITIS; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERURICEMIA; INJECTION SITE CONTUSION; INJECTION SITE REACTION; INSULIN BLOOD LEVEL; MALE; METASTASIS; MICTURITION DISORDER; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RASH; SIDE EFFECT; SOLID TUMOR; URIC ACID BLOOD LEVEL; WEIGHT REDUCTION; ADRENAL CORTEX TUMOR; AREA UNDER THE CURVE; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG ANTAGONISM; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; AGED; ANOREXIA; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; GROWTH HORMONE; HUMANS; HYPERGLYCEMIA; INFUSIONS, INTRAVENOUS; INSULIN; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NAUSEA; RECEPTOR, IGF TYPE 1; TREATMENT OUTCOME; YOUNG ADULT;

EID: 75749102231     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1083-9     Document Type: Article

References (39)

1. D Le Roith 1997 Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors N Engl J Med 336 9 633 640 10.1056/NEJM199702273360907 1:CAS:528:DyaK2sXhvVehs78%3D 9032050 (Pubitemid 27093410)
2. MR Cardillo S Monti F Di Silverio V Gentile F Sciarra V Toscano 2003 Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer Anticancer Res 23 5A 3825 3835 1:CAS:528:DC%2BD2cXkvFem 14666684
3. YS Chang G Kong S Sun D Liu AK El-Naggar FR Khuri, et al. 2002 Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer Clin Cancer Res 8 12 3796 3802 1:CAS:528:DC%2BD38XpslCjt7c%3D 12473592
4. R Durai W Yang S Gupta AM Seifalian MC Winslet 2005 The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge Int J Colorectal Dis 20 3 203 220 10.1007/s00384-004-0675-4 15650828 (Pubitemid 40552999)
5. SE Hankinson WC Willett GA Colditz DJ Hunter DS Michaud B Deroo, et al. 1998 Circulating concentrations of insulin-like growth factor-I and risk of breast cancer Lancet 351 9113 1393 1396 10.1016/S0140-6736(97)10384-1 1:STN:280:DyaK1c3lsVansw%3D%3D 9593409 (Pubitemid 28209997)
6. KR Kalli OI Falowo LK Bale MA Zschunke PC Roche CA Conover 2002 Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling Endocrinology 143 9 3259 3267 10.1210/en.2001-211408 1:CAS:528:DC%2BD38XmsVSgt7g%3D 12193537 (Pubitemid 34925700)
7. D Sachdev SL Li JS Hartell Y Fujita-Yamaguchi JS Miller D Yee 2003 A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I Cancer Res 63 3 627 635 1:CAS:528:DC%2BD3sXosVyisw%3D%3D 12566306
8. S Abe T Funato S Takahashi H Yokoyama J Yamamoto Y Tomiya, et al. 2006 Increased expression of insulin-like growth factor i is associated with Ara-C resistance in leukemia Tohoku J Exp Med 209 3 217 228 10.1620/tjem.209.217 1:CAS:528:DC%2BD28XntVSrsr4%3D 16778368 (Pubitemid 43905553)
9. GW Allen C Saba EA Armstrong SM Huang S Benavente DL Ludwig, et al. 2007 Insulin-like growth factor-I receptor signaling blockade combined with radiation Cancer Res 67 3 1155 1162 10.1158/0008-5472.CAN-06-2000 1:CAS:528: DC%2BD2sXht1ynsLY%3D 17283150 (Pubitemid 46270773)
10. A Camirand Y Lu M Pollak 2002 Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors cause synergistic inhibition of growth in HER2-overexpressing breast cancer cells Med Sci Monit 8 12 BR521 BR526 1:CAS:528:DC%2BD3sXhtVGiu74%3D 12503030
11. C Desbois-Mouthon W Cacheux MJ Blivet-Van Eggelpoel V Barbu L Fartoux R Poupon, et al. 2006 Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib Int J Cancer 119 11 2557 2566 10.1002/ijc.22221 1:CAS:528:DC%2BD28XhtFygtbfO 16988945 (Pubitemid 44691308)
12. JM Gee JF Robertson E Gutteridge IO Ellis SE Pinder M Rubini, et al. 2005 Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer Endocr Relat Cancer 12 suppl 1 S99 S111 10.1677/erc.1.01005 1:CAS:528: DC%2BD2MXhtFyitb3N 16113104 (Pubitemid 41395417)
13. JM Knowlden IR Hutcheson D Barrow JM Gee RI Nicholson 2005 Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor Endocrinology 146 11 4609 4618 10.1210/en.2005-0247 1:CAS:528:DC%2BD2MXhtFGqur7O 16037379 (Pubitemid 41446598)
14. X Wan LJ Helman 2002 Effect of insulin-like growth factor II on protecting myoblast cells against cisplatin-induced apoptosis through p70 S6 kinase pathway Neoplasia 4 5 400 408 10.1038/sj.neo.7900242 1:CAS:528: DC%2BD38XmtlWlurk%3D 12192598 (Pubitemid 34976955)
15. LR Wiseman MD Johnson AE Wakeling AE Lykkesfeldt FE May BR Westley 1993 Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells Eur J Cancer 29A 16 2256 2264 10.1016/0959-8049(93) 90218-5 1:CAS:528:DyaK2cXktVSgtLo%3D 8110496 (Pubitemid 24053004)
16. D Yin N Tamaki AD Parent JH Zhang 2005 Insulin-like growth factor-I decreased etoposide-induced apoptosis in glioma cells by increasing bcl-2 expression and decreasing CPP32 activity Neurol Res 27 1 27 35 10.1179/016164105X18151 1:CAS:528:DC%2BD2MXhs1eitL4%3D 15829155 (Pubitemid 40189601)
17. RT Kurmasheva PJ Houghton 2006 IGF-I mediated survival pathways in normal and malignant cells Biochim Biophys Acta 1766 1 1 22 1:CAS:528: DC%2BD28XotVyrurY%3D 16844299
18. AA Samani S Yakar D Leroith P Brodt 2007 The role of the IGF system in cancer growth and metastasis: overview and recent insights Endocr Rev 28 1 20 47 10.1210/er.2006-0001 1:CAS:528:DC%2BD2sXjtFCgsrg%3D 16931767 (Pubitemid 46220849)
19. MN Pollak ES Schernhammer SE Hankinson 2004 Insulin-like growth factors and neoplasia Nat Rev Cancer 4 7 505 518 10.1038/nrc1387 1:CAS:528: DC%2BD2cXlt1Oktro%3D 15229476
20. P Icard P Goudet C Charpenay B Andreassian B Carnaille Y Chapuis, et al. 2001 Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group World J Surg 25 7 891 897 10.1007/s00268-001-0047-y 1:STN:280:DC%2BD3MrisVGisg%3D%3D 11572030 (Pubitemid 32666390)
21. BL Wajchenberg MA Albergaria Pereira BB Medonca AC Latronico P Campos Carneiro VA Alves, et al. 2000 Adrenocortical carcinoma: clinical and laboratory observations Cancer 88 4 711 736 10.1002/(SICI)1097-0142(20000215)88:4<711:: AID-CNCR1>3.0.CO;2-W 1:STN:280:DC%2BD3c7ksFKqtA%3D%3D 10679640 (Pubitemid 30091090)
22. LS Kirschner 2006 Emerging treatment strategies for adrenocortical carcinoma: a new hope J Clin Endocrinol Metab 91 1 14 21 10.1210/jc.2005-1739 1:CAS:528:DC%2BD28Xms1aitw%3D%3D 16234301 (Pubitemid 43069108)
23. M Terzolo A Angeli M Fassnacht F Daffara L Tauchmanova PA Conton, et al. 2007 Adjuvant mitotane treatment for adrenocortical carcinoma N Engl J Med 356 23 2372 2380 10.1056/NEJMoa063360 1:CAS:528:DC%2BD2sXmt1WnsLg%3D 17554118 (Pubitemid 46883771)
24. TJ Giordano DG Thomas R Kuick M Lizyness DE Misek AL Smith, et al. 2003 Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis Am J Pathol 162 2 521 531 1:CAS:528:DC%2BD3sXhtlKru70%3D 12547710
25. D Velazquez-Fernandez C Laurell J Geli A Hoog J Odeberg M Kjellman, et al. 2005 Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy Surgery 138 6 1087 1094 10.1016/j.surg.2005.09.031 16360395 (Pubitemid 41797349)
26. AN West GA Neale S Pounds BC Figueredo C Rodriguez Galindo MA Pianovski, et al. 2007 Gene expression profiling of childhood adrenocortical tumors Cancer Res 67 2 600 608 10.1158/0008-5472.CAN-06-3767 1:CAS:528:DC%2BD2sXmtVKktw%3D%3D 17234769 (Pubitemid 46192198)
27. MM Weber CJ Auernhammer W Kiess D Engelhardt 1997 Insulin-like growth factor receptors in normal and tumorous adult human adrenocortical glands Eur J Endocrinol 136 3 296 303 10.1530/eje.0.1360296 1:CAS:528:DyaK2sXitl2jsb0%3D 9100555
28. BD Cohen DA Baker C Soderstrom G Tkalcevic AM Rossi PE Miller, et al. 2005 Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751, 871 Clin Cancer Res 11 5 2063 2073 10.1158/1078-0432.CCR-04-1070 1:CAS:528:DC%2BD2MXitVKrtr0%3D 15756033 (Pubitemid 40471873)
29. P Haluska HM Shaw GN Batzel D Yin JR Molina LR Molife, et al. 2007 Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors Clin Cancer Res 13 19 5834 5840 10.1158/1078-0432.CCR-07-1118 1:CAS:528: DC%2BD2sXhtFSntLrE 17908976 (Pubitemid 47583908)
30. FM Barlaskar AC Spalding JH Heaton R Kuick AC Kim DG Thomas, et al. 2008 Preclinical targeting of the type 1 insulin-like growth factor receptor in adrenocortical carcinoma J Clin Endocrinol Metab 94 1 204 212 10.1210/jc.2008-1456 18854392
31. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New York (NY)
32. MQ Lacy M Alsina R Fonseca ML Paccagnella CL Melvin D Yin, et al. 2008 Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulin-like growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma J Clin Oncol 26 19 3196 3203 10.1200/JCO.2007.15.9319 1:CAS:528:DC%2BD1cXptlKgtb8%3D 18474873
33. Z Laron B Klinger B Erster S Anin 1988 Effect of acute administration of insulin-like growth factor I in patients with Laron-type dwarfism Lancet 2 8621 1170 1172 10.1016/S0140-6736(88)90236-X 1:STN:280:DyaL1M%2FjvVymtw%3D%3D 2903379
34. G Di Cola MH Cool D Accili 1997 Hypoglycemic effect of insulin-like growth factor-1 in mice lacking insulin receptors J Clin Invest 99 10 2538 2544 10.1172/JCI119438 1:CAS:528:DyaK2sXjsVGqt7Y%3D 9153298
35. M Gronborg BS Wulff JS Rasmussen T Kjeldsen S Gammeltoft 1993 Structure-function relationship of the insulin-like growth factor-I receptor tyrosine kinase J Biol Chem 268 31 23435 23440 1:STN:280:DyaK2c%2FktlWguw%3D%3D 7693688
36. JC Bruning MD Michael JN Winnay T Hayashi D Horsch D Accili, et al. 1998 A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance Mol Cell 2 5 559 569 10.1016/S1097-2765(00)80155-0 1:CAS:528:DyaK1MXhtV2muw%3D%3D 9844629
37. PY Chang H Benecke Y Le Marchand-Brustel J Lawitts DE Moller 1994 Expression of a dominant-negative mutant human insulin receptor in the muscle of transgenic mice J Biol Chem 269 23 16034 16040 1:CAS:528:DyaK2cXkt1OnsLk%3D 8206901
38. DD Karp LG Paz-Ares S Novello P Haluska L Garland F Cardenal, et al. 2009 Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer J Clin Oncol 27 15 2516 2522 10.1200/JCO.2008.19.9331 1:CAS:528:DC%2BD1MXmvVOhsb4%3D 19380445
39. A Gualberto CL Melvin A Dean AL Ang JM Reynolds AV Lee, et al. 2008 Characterization of NSCLC patients responding to anti-IGF-IR therapy J Clin Oncol 26 8000